Why Belite Bio Stock Soared on Monday

BLTE -2.06%

Key Points

• The biotech's Stargardt disease drug did well in a late-stage clinical trial.

• This is an eye affliction that can lead to loss of central vision.

• 10 stocks we like better than Belite Bio ›

The mood on the stock market was gloomy on Monday, but apparently somebody forgot to notify Belite Bio (NASDAQ: BLTE). The company, a clinical-stage biotech focused on developing therapies for eye disorders, saw its share price zoom 12% higher thanks to an encouraging update from the laboratory.

Seeing more clearly

That morning, Belite announced that its leading drug candidate, tinlarebant, met its primary endpoint in a phase 3 trial. The medicine was being tested to determine its efficacy in treating adolescents with Stargardt disease, a condition that can lead to loss of central vision.

Tinlarebant was found to produce a nearly 36% reduction in lesion growth, a key feature of the affliction, compared to a placebo. Belite added that it recorded minimal change in visual acuity after 24 months.

In its press release touting the readout, Belite quoted CEO Tom Lin as saying that "Not only was tinlarebant shown to be efficacious in slowing retinal degeneration, but this is also the first time that an oral treatment was able to demonstrate a clinically meaningful outcome in retinal degenerative disease."

The healthcare company said that it aims to submit New Drug Applications for the medication in the first half of next year.

A vision for the future

As always, I must caution that, regardless of how well a drug performs in a late-stage trial, regulatory approval is by no means guaranteed.

However, tinlarebant is clearly efficacious in treating a disease that is pernicious and highly problematic. Given that, I'd say at least a U.S. Food and Drug Administration (FDA) nod is likely. Monday's investor reaction, in my opinion, was fully justified.

Should you buy stock in Belite Bio right now?

Before you buy stock in Belite Bio, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Belite Bio wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $580,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,084,986!*

Now, it’s worth noting Stock Advisor’s total average return is 1,004% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of December 1, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Why Belite Bio Stock Soared on Monday was originally published by The Motley Fool